Fluidigm, a company that makes integrated fluidic circuit systems, which make life science research easier by allowing researches to perform thousands of biochemical measurements, has filed for an initial public offering.
The San Francisco company plans to sell up to $86.25 million in common stock.
Fluidigm’s revenues rose to $7.3 million from $6.4 million. However, it reported growing losses: $25.5 million in 2007, up from a loss of $23.6 million in 2006.
Fluidigm has raised nearly $200 million funding over the past decade. Shareholders include EDB Investments (which has a 13.49 percent ownersip stake) Fidelity Contrafund (9.38 percent), Versant Venture Capital (8.83 percent), EuclidSR Partners (7.35 percent) and Smallcap World Fund (6.57 pecent); Interwest Investors (5.67 percent), Alloy Ventures (5.6 percent) and Lehman Brothers Healthcare Venture Capital (5.54 percent), according to the filing.